USD 2.15
(0.0%)
Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Operating Cash Flow | -12.24 Million | -237 Thousand | 2.64 Million | -7.9 Million | -2.31 Million | -61.01 Million |
Net Income | -12.47 Million | 709 Thousand | 18.5 Million | -41.52 Million | -11.25 Million | -92.59 Million |
Depreciation & Amortization | 1.03 Million | 1.95 Million | 1.62 Million | 8.96 Million | 4.9 Million | 9.99 Million |
Deferred income taxes | -259.67 Thousand | 2.17 Million | 3.51 Million | 6.27 Million | 2.53 Million | 5.44 Million |
Stock-based compensation | -1.66 Million | 1.94 Million | 3.79 Million | 151.97 Thousand | 1.98 Million | 2.77 Million |
Change in working capital | 585.54 Thousand | -5.47 Million | -9.6 Million | -4.15 Million | -7.25 Million | 20.7 Million |
Other non-cash items | 534.73 Thousand | -1.54 Million | -15.17 Million | 22.38 Million | 16.29 Million | -7.33 Million |
Investing Cash Flow | 773.93 Thousand | -2 Million | -1.21 Million | 325.59 Thousand | 2.68 Million | 1.03 Million |
Investments in PPE | -402.24 Thousand | -850 Thousand | -1.05 Million | - | - | -15.52 Thousand |
Acquisitions | - | - | - | - | 69.02 Thousand | - |
Investment purchases | - | -1.11 Million | -164.81 Thousand | - | - | - |
Sales/Maturities of investments | 1.17 Million | - | - | 342.79 Thousand | 2.61 Million | 1.03 Million |
Other Investing Activities | -1.00 | -45.8 Thousand | -1464.00 | -17.2 Thousand | 2.09 Million | 1.04 Million |
Financing Cash Flow | 12.95 Million | -8.77 Million | 10.89 Million | -7.52 Million | -4.36 Million | -11.64 Million |
Debt repayment | -12.95 Million | - | - | -6.38 Million | - | - |
Dividends payments | - | - | - | -14.3 Million | -4.36 Million | -11.64 Million |
Common Stock Repurchased | - | - | - | -80 Million | - | - |
Common Stock Issuance | - | - | 19.65 Million | - | - | - |
Other Financing Activities | 13.00 | -8.77 Million | -8.76 Million | 86.06 Million | - | - |
Accounts receivables | 192 Thousand | -152 Thousand | 1.17 Million | 267.4 Thousand | 16.17 Million | 11.38 Million |
Accounts payables | -889 Thousand | 1.06 Million | -6.72 Million | 1.46 Million | -14.54 Million | 10.33 Million |
Inventory | 1.82 Million | - | -2.68 Million | 473.2 Thousand | 653.42 Thousand | -9853.00 |
Other working capital | -542 Thousand | -6.38 Million | -1.37 Million | -6.35 Million | -9.54 Million | -1 Million |
Cash at beginning of period | 18.37 Million | 29.58 Million | 17.66 Million | 31.74 Million | 36.17 Million | 110.89 Million |
Cash at end of period | 19.54 Million | 18.38 Million | 29.58 Million | 17.66 Million | 31.74 Million | 36.17 Million |
Capital Expenditure | -402.24 Thousand | -850 Thousand | -1.05 Million | - | - | -15.52 Thousand |
Effect of forex changes on cash | -206 Thousand | -183 Thousand | -396.6 Thousand | 1.01 Million | -421.17 Thousand | -3.09 Million |
Net cash flow / Change in cash | 1.16 Million | -11.2 Million | 11.92 Million | -14.08 Million | -4.42 Million | -74.71 Million |
Free Cash Flow | -12.64 Million | -1.08 Million | 1.59 Million | -7.9 Million | -2.31 Million | -61.02 Million |
Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | -5.59 Million | -6 Million | -4.11 Million | -12.47 Million | -4.17 Million | -1.29 Million |
Depreciation & Amortization | 152.96 Thousand | 178.2 Thousand | 179.83 Million | 1.03 Million | 159 Thousand | 166 Thousand |
Deferred income taxes | -42.09 Thousand | -54.75 Thousand | -185.49 Thousand | -259.67 Thousand | 1.07 Million | 455 Thousand |
Stock-based compensation | 593 Thousand | 507 Thousand | 150 Thousand | -1.66 Million | 48 Thousand | -2.05 Million |
Change in working capital | 5.6 Million | -298.65 Thousand | 393.47 Thousand | 585.54 Thousand | 1.69 Million | -175 Thousand |
Other non-cash items | 798.64 Thousand | -383.28 Thousand | -176.97 Million | 534.73 Thousand | 1.58 Million | 1.83 Million |
Investing Cash Flow | -182.06 Thousand | -190.14 Thousand | -179.29 Thousand | 773.93 Thousand | -35 Thousand | 373 Thousand |
Investments in PPE | -181.14 Thousand | -199.1 Thousand | -153.26 Thousand | -402.24 Thousand | -45 Thousand | -22 Thousand |
Acquisitions | - | - | - | - | - | - |
Investment purchases | - | - | - | - | - | - |
Sales/Maturities of investments | -927.02 | 8959.80 | -26.02 Thousand | 1.17 Million | 9134.80 | 398.84 Thousand |
Other Investing Activities | -1000.00 | 9000.00 | -1.00 | -1.00 | 865.20 | -3842.00 |
Financing Cash Flow | - | -5.08 Million | 26.75 Thousand | 12.95 Million | 8.37 Million | - |
Debt repayment | - | - | -761.84 Thousand | -12.95 Million | -12.61 Million | - |
Dividends payments | - | - | - | - | - | - |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | - |
Other Financing Activities | - | -5.08 Million | 788.59 Thousand | 13.00 | 8.37 Million | - |
Accounts receivables | 4.12 Million | -932.81 Thousand | -204 Thousand | 192 Thousand | 1.21 Million | 444 Thousand |
Accounts payables | 372.6 Thousand | -631.16 Thousand | 978 Thousand | -889 Thousand | -778 Thousand | -845 Thousand |
Inventory | - | - | 535.47 Thousand | 1.82 Million | 505 Thousand | 66 Thousand |
Other working capital | 1.1 Million | 1.26 Million | -916 Thousand | -542 Thousand | 754 Thousand | 160 Thousand |
Cash at beginning of period | 11.23 Million | 19.54 Million | 20.81 Million | 18.37 Million | 12.18 Million | 12.92 Million |
Cash at end of period | 16.33 Million | 11.23 Million | 19.54 Million | 19.54 Million | 20.91 Million | 12.18 Million |
Capital Expenditure | -181.14 Thousand | -199.1 Thousand | -153.26 Thousand | -402.24 Thousand | -45 Thousand | -22 Thousand |
Effect of forex changes on cash | 62 Thousand | 314 Thousand | -241 Thousand | -206 Thousand | 11 Thousand | -47 Thousand |
Net cash flow / Change in cash | 5.1 Million | -8.31 Million | -1.27 Million | 1.16 Million | 8.73 Million | -739 Thousand |
Free Cash Flow | 4.93 Million | -8.68 Million | -1.04 Million | -12.64 Million | 336 Thousand | -1.08 Million |
MMTIF
KREVF
2270
0II3
TORNTPHARM
KROS